Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Pickings for concurrent treatment are slim in Ending the HIV Epidemic rural communities.
Overdose deaths rose by nearly 5% in 2019, and the pandemic could make matters worse.
This is one of many ways that people who use drugs can engage in harm reduction during the coronavirus pandemic.
A national survey found that primary care physicians had little interest in prescribing buprenorphine or naltrexone.
Even after federal regulators relaxed rules requiring daily clinic visits, these bad actors are still bringing patients in for monitoring.
Experts are calling for greater flexibility in clinicians’ ability to deliver treatments for opioid use disorder.
A systematic review of hep C treatment outcomes in this population shows they have high cure rates and relatively low reinfection rates.
Researchers found critical gaps in the scientific knowledge about the opioid epidemic.
Researchers followed people with a drug-injection history who had been cured of hepatitis C and were receiving addiction treatment.
A literature review shows promising signs that teenagers, like adults, can benefit from methadone, buprenorphine and naltrexone.
A group of experts has issued a call to arms, spotlighting missed opportunities for addiction treatment in hospital settings.
Research suggests that individuals receiving opioid replacement therapy have a better chance of beating hep C through this method.
Until now, international studies had proved only that the approaches reduced injecting risk behavior.
Advocates argue that authorities planning for natural disasters must factor in the needs of those suffering from addiction and in recovery.
Few recontracted the virus after being cured, and some of those who got reinfected spontaneously cleared it.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.